Viewing Study NCT05139004


Ignite Creation Date: 2025-12-24 @ 9:07 PM
Ignite Modification Date: 2026-02-06 @ 6:17 AM
Study NCT ID: NCT05139004
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2025-07-08
First Post: 2021-11-22
Is Gene Therapy: True
Has Adverse Events: False

Brief Title: 90Y-DOTA-anti-CD25 Basiliximab, Fludarabine, Melphalan, and Total Marrow and Lymphoid Irradiation for the Treatment of High-Risk Acute Leukemia or Myelodysplastic Syndrome
Sponsor: City of Hope Medical Center
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Acute Lymphoblastic Leukemia View
None Acute Myeloid Leukemia View
None Myelodysplastic Syndrome View
None Secondary Acute Myeloid Leukemia View
Keywords: